Monday, March 02, 2009

NanoViricides - Big News!

This is huge news for NanoViricides. Those of us familiar with the Company should know just how huge this news is as it confirms the viability of the underlying science by a major pharmaceutical company. It is that confirmation which should ignite these shares toward a significant and unbelievable market capitalization.


NanoViricides, Inc. Signs Agreement with a Major Pharma

Monday March 2, 7:00 am ET

Material Transfer Agreement is First Step Towards Licensing Agreement

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a Material Transfer Agreement with a major pharmaceutical company (“Party”). The Agreement initially entails evaluation of one of the Company’s nanoviricide drug candidates by an independent consultant chosen by the Party. This drug candidate has been designed to eradicate viral infections of the external eye, including those caused by adenovirus and herpes virus (“HSV”). It is the understanding of the Parties that, should the testing results be favorable, they will enter into good faith negotiations for a potential long-term, exclusive, worldwide licensing agreement for the development and commercialization of the drug.

“This agreement is the first step towards a potential licensing agreement,” said Eugene Seymour, MD, MPH, CEO of Nanoviricides, Inc, adding, “It clearly signals that our technology is now attracting serious attention from major Pharma companies.”

The terms of the Agreement do not allow the disclosure of the identity of the Party or the exact terms of the Agreement.

HSV and some adenoviruses cause most of the cases of keratitis, a serious infection of the cornea. Importantly, HSV infection can lead to corneal scarring that may necessitate corneal transplantation. In addition, some adenoviruses cause a majority of conjunctivitis cases (“pink eye”). The remaining cases of conjunctivitis, caused by bacteria, are treatable with topical antibiotics. Currently, there are no effective treatments for viral diseases of the exterior portion of the eye.

The Company has already demonstrated strong efficacy against an adenovirus-caused external eye disease called epidemic kerato-conjunctivitis (EKC). Rapid clinical improvement in the treated animals was reported by independent researchers who tested the effects of the nanoviricides drug candidate against adenoviral EKC. Based on computer modeling, the Company believes that the broad-spectrum nature of the ligand used in this nanoviricide should enable it to be effective against HSV.

The total market for viral conjunctivitis is estimated to be in the billions of dollars. The incidence of severe herpes keratitis is estimated to be 250,000 cases per year in the USA. In Japan, where EKC is a reportable disease, it is estimated that there are at least one million cases per year. The number of cases of non-specific conjunctivitis (pink eye) is considered to be far greater, possibly into tens of millions in the US, and into hundreds of millions worldwide.

About NanoViricides:

NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.


Anonymous said...

Great News on NNVC....Finally!! Not a good day for The Market me thinks tho....last leg down, final dagger thrust and deep? Gary

Anonymous said...

Any guesses as to The Major Pharma?

Anonymous said...

Oh, and thanks again with you at .085 when you brought it to our attention, Gary

Anonymous said...

not a whole lot of price movement though ...

Anonymous said...

I think the announcement with no name and no term really disappoints

now actually down to 67 cents

Anonymous said...

Allan, with no terms being given, how do you know NNVC is giving their stuff away free, I am concerned

Anonymous said...

it is just getting worse, down to 63 cents now

Allan said...

You folks are watching too closely, so closely in fact that you are missing the forest for the trees. Since the bear market began in late July 2007, the S&P is down 50%. NNVC was trading between 0.75 and 0.85 at the time, so lets say it was trading at 0.80. At 0.70, it is down a whopping 12.5%. Let's see, one asset is down 50% and the other is down 12.5%. Which one has been a better buy and hold?

Anonymous said...

I suspect SPX is finishing 5 of 3 of 5 of primary 1.

Mike, Alan, what do you think the count is?


Anonymous said...

Re "no name and no term": in the current very bearish climate, that seems indeed to be the reason why today's announcement is not enough to make NNVC go against the tide. But as Allan points out, the stock is not doing badly relative to the market. This is a waiting game, and today's little up/down flurry means exactly nothing.

-Alex K

Anonymous said...

And very difficult for even the best companies to be a winner on a day like today as the world funnels downward into oblivian

Allan said...

Re: Any guesses as to The Major Pharma?

There are some names being floated around on the iHub board:

Re: Mike, Alan, what do you think the count is?

An odd number, a Fiboancci number, an impulsive number, all pointing down. That's about as close as I can get right now.

Anonymous said...

You've guys had made one heck of a call on SPX. Congratulations.


Anonymous said...

Try MELA instead. I think NNVC is trying to get someone to evaluate their eye drug after they posted dubious rabbit images sometime back.


Tom D said...

Herpes or adenovirus conjunctivitis tends to be recurrent, so you don't have agony in your eye just one time. If you've known people who've had it, as I have, you can almost feel their excruciating pain.

This is not a do-gooder, politically correct drug idea. This is the real thing, IF IT'S REAL, and someone who IS real wants to know and will pay to find out. It's a gravy train for NNVC if they are for real. They would have amazingly good traction for their other projects.

Allan said...

Finally, someone who gets it; very nicely put.

Ubreako said...

I spent the last 10 days researching NNVC. Going thru the blog, reading the ihub material and going thru the tidbits provided by Mr Alan.

This is a very good risk reward play and it might be silly to trade in and out of this name. Thse type of stocks are hidden gems, once realised the gap up activity will be insane !

I have put my position on today and the next time i write on this blog will be in 2014. Many of us talk about owning a Microsoft and growing usd1000 to 2million.....opportunity knocks with this stock and i see alot of skeptics. I guess Google was a flop to these people as well.

This investment will either be a zero or 1 million USD in 5 year. Theres alot of consolidation in the pharmaceutical industry and poor product pipelines. My biggest fear will be this company gets taken over at 10 bucks thus limiting its upside.

Long 10,000 NNVC shares